GlobalData (DATA) investor relations material

Financial performance and trading update

• Revenue growth for H1 2026 is expected at approximately 3%, with underlying growth of 1%.

• Contracted Forward Revenue is set to grow by about 6%, with underlying growth of 1%.

• Adjusted EBITDA is projected to increase by 4-5% for the period, with full-year EBITDA expected at the low end of consensus.

• Renewal rates remain strong at around 89%, indicating resilient customer relationships.

• Non-Healthcare division saw 1% underlying revenue growth and 2% Contracted Forward Revenue growth.

Business developments and strategic initiatives

• Integration of AI-powered Ava Research Assistant into Microsoft 365 Copilot enhances workflow intelligence.

• Operating model is evolving to pair platform agility with market-focused business units.

• Healthcare division's revenue grew 1%, but Contracted Forward Revenue declined 1% due to a challenging pharmaceuticals market.

• Acquisition of Cambridge Healthcare strengthens competitive intelligence in the pharmaceuticals sector.

• Board believes the sum-of-the-parts value of the portfolio exceeds current market capitalization.

Capital allocation and shareholder returns

• A £30 million tender offer will launch on 10 July 2026, bringing total capital returns for the year to £45 million, plus £8 million carried over from 2025.

• Ongoing £5 million share buy-back program remains in place.

• Non-Healthcare facility upsized by £60 million to £245 million, and Healthcare facility extended to December 2028.